Two recent phase 2 clinical trials reported promising benefits and acceptable toxicity of neoadjuvant anti-PD-1 antibody combined with antiangiogenic agent in patients with resectable NSCLC [50, 51]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.